Display options
Cite
Obara T, Blonski M, Brzenczek C, et al. Adult Diffuse Low-Grade Gliomas: 35-Year Experience at the Nancy France Neurooncology Unit. Front Oncol. 2020;10:574679doi: 10.3389/fonc.2020.574679.
Obara, T., Blonski, M., Brzenczek, C., Mézières, S., Gaudeau, Y., Pouget, C., Gauchotte, G., Verger, A., Vogin, G., Moureaux, J. M., Duffau, H., Rech, F., & Taillandier, L. (2020). Adult Diffuse Low-Grade Gliomas: 35-Year Experience at the Nancy France Neurooncology Unit. Frontiers in oncology, 10574679. https://doi.org/10.3389/fonc.2020.574679
Obara, Tiphaine, et al. "Adult Diffuse Low-Grade Gliomas: 35-Year Experience at the Nancy France Neurooncology Unit." Frontiers in oncology vol. 10 (2020): 574679. doi: https://doi.org/10.3389/fonc.2020.574679
Obara T, Blonski M, Brzenczek C, Mézières S, Gaudeau Y, Pouget C, Gauchotte G, Verger A, Vogin G, Moureaux JM, Duffau H, Rech F, Taillandier L. Adult Diffuse Low-Grade Gliomas: 35-Year Experience at the Nancy France Neurooncology Unit. Front Oncol. 2020 Oct 28;10:574679. doi: 10.3389/fonc.2020.574679. eCollection 2020. PMID: 33194684; PMCID: PMC7656991.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2020 Oct 28;10:574679. doi: 10.3389/fonc.2020.574679. eCollection 2020.

Adult Diffuse Low-Grade Gliomas: 35-Year Experience at the Nancy France Neurooncology Unit.

Frontiers in oncology

Tiphaine Obara, Marie Blonski, Cyril Brzenczek, Sophie Mézières, Yann Gaudeau, Celso Pouget, Guillaume Gauchotte, Antoine Verger, Guillaume Vogin, Jean-Marie Moureaux, Hugues Duffau, Fabien Rech, Luc Taillandier

Affiliations

  1. Centre de Recherche en Automatique Nancy France - UMR 7039 - BioSiS Department, Faculty of Medicine, Université de Lorraine, Vandoeuvre-lès-Nancy, France.
  2. Neurology Departement, Neurooncology Unit, CHRU, Nancy, France.
  3. Department of Mathematics, Elie Cartan Institute, Nancy, France.
  4. INRIA Biology, Genetics and Statistics, Nancy, France.
  5. Department of Pathology, CHRU, Nancy, France.
  6. Centre de Ressources Biologiques, BB-0033-00035, CHRU Nancy, France.
  7. Department of Nuclear Medicine and Nancyclotep Imaging Platform, CHRU Nancy, France.
  8. IADI, INSERM U1254, Lorraine University, Vandoeuvre-lès-Nancy, France.
  9. UMR 7365 CNRS, IMoPA Biopole Lorraine University Faculty of Medicine, Université de Lorraine, Vandoeuvre-lès-Nancy, France.
  10. Department of Radiation Therapy, Baclese Radiation Therapy Centre, Esch/Alzette, Luxembourg.
  11. Department of Neurosurgery, Montpellier University Medical Center, Gui de Chauliac Hospital, Montpellier, France.
  12. Team "Plasticity of Central Nervous System, Stem Cells and Glial Tumors", U1051 Laboratory, National Institute for Health and Medical Research (INSERM), Institute for Neurosciences of Montpellier, Montpellier University Medical Center, Montpellier, France.
  13. Department of Neurosurgery, CHRU, Nancy, France.

PMID: 33194684 PMCID: PMC7656991 DOI: 10.3389/fonc.2020.574679

Abstract

BACKGROUND: To report survival, spontaneous prognostic factors, and treatment efficacy in a French monocentric cohort of diffuse low-grade glioma (DLGG) patients over 35 years of follow-up.

METHODS: A monocentric retrospective study of 339 patients diagnosed with a new DLGG between 01/01/1982 and 01/01/2017 was created. Inclusion criteria were patient age ≥18 years at diagnosis and histological diagnosis of WHO grade II glioma (according to 1993, 2007, and 2016 WHO classifications). The survival parameters were estimated using the Kaplan-Meier method with a 95% confidence interval. Differences in survival were tested for statistical significance by the log-rank test. Factors were considered significant when

RESULTS: A total of 339 patients were included with a median follow-up of 8.7 years. The Kaplan-Meier median overall survival was 15.7 years. At the time of radiological diagnosis, Karnofsky Performance Status score and initial tumor volume were significant independent prognostic factors. Oncological prognostic factors were the extent of resection for patients who underwent surgery and the timing of radiotherapy for those concerned. In this study, patients who had delayed radiotherapy (provided remaining low grade) did not have worse survival compared with patients who had early radiotherapy. The functional capabilities of the patients were preserved enough so that they could remain independent during at least three quarters of the follow-up.

CONCLUSION: This large monocentric series spread over a long time clarifies the effects of different therapeutic strategies and their combination in the management of DLGG.

Copyright © 2020 Obara, Blonski, Brzenczek, Mézières, Gaudeau, Pouget, Gauchotte, Verger, Vogin, Moureaux, Duffau, Rech and Taillandier.

Keywords: chemotherapy; diffuse low-grade glioma; prognosis; quality of life; radiation therapy; surgery; survival

References

  1. J Neurosurg Sci. 2015 Dec;59(4):351-60 - PubMed
  2. J Neurol Neurosurg Psychiatry. 2005 Jun;76(6):845-51 - PubMed
  3. N Engl J Med. 2016 Apr 7;374(14):1344-55 - PubMed
  4. Acta Neurochir (Wien). 2016 Jan;158(1):51-8 - PubMed
  5. Lancet. 2005 Sep 17-23;366(9490):985-90 - PubMed
  6. PLoS One. 2018 Sep 20;13(9):e0203639 - PubMed
  7. World Neurosurg. 2014 Jul-Aug;82(1-2):e129-31 - PubMed
  8. J Neurosurg. 2001 Nov;95(5):735-45 - PubMed
  9. Clin Neurol Neurosurg. 2013 Dec;115(12):2508-13 - PubMed
  10. Oncotarget. 2018 Sep 14;9(72):33623-33633 - PubMed
  11. Cancer. 1994 Sep 15;74(6):1784-91 - PubMed
  12. Clin Neurol Neurosurg. 2012 Oct;114(8):1135-44 - PubMed
  13. Cochrane Database Syst Rev. 2014 May 15;(5):CD007104 - PubMed
  14. Acta Neuropathol. 2018 Apr;135(4):601-615 - PubMed
  15. J Clin Oncol. 2002 Apr 15;20(8):2076-84 - PubMed
  16. Lancet Oncol. 2016 Nov;17(11):1521-1532 - PubMed
  17. World Neurosurg. 2018 Dec;120:e762-e775 - PubMed
  18. Acta Neuropathol. 2007 Aug;114(2):97-109 - PubMed
  19. Ann Oncol. 2017 Aug 1;28(8):1942-1948 - PubMed
  20. J Neurooncol. 2015 Dec;125(3):503-30 - PubMed
  21. Neuro Oncol. 2017 Feb 1;19(2):242-251 - PubMed
  22. Curr Oncol. 2018 Feb;25(1):e33-e39 - PubMed
  23. Am J Clin Oncol. 2013 Dec;36(6):612-9 - PubMed
  24. World Neurosurg. 2019 Jan 23;: - PubMed
  25. Neurology. 2000 Apr 11;54(7):1442-8 - PubMed
  26. Brain Pathol. 1993 Jul;3(3):255-68 - PubMed
  27. Expert Opin Drug Saf. 2009 Jul;8(4):493-9 - PubMed
  28. J Neurosurg. 2003 Nov;99(5):854-62 - PubMed
  29. J Clin Neurosci. 2018 Dec;58:124-129 - PubMed
  30. Neurosurgery. 2012 Sep;71(3):729-39; discussion 739-40 - PubMed
  31. J Neurooncol. 2015 Dec;125(3):551-83 - PubMed
  32. J Neurooncol. 2012 Jun;108(2):309-18 - PubMed
  33. Neuro Oncol. 2009 Aug;11(4):437-45 - PubMed
  34. J Clin Oncol. 2012 Jul 10;30(20):2559-65 - PubMed
  35. J Neurooncol. 2019 Oct;145(1):115-123 - PubMed
  36. Am J Pathol. 2010 Dec;177(6):2708-14 - PubMed
  37. Neuro Oncol. 2015 Mar;17(3):332-42 - PubMed
  38. Neuro Oncol. 2009 Apr;11(2):176-82 - PubMed
  39. BMC Cancer. 2018 Jan 6;18(1):48 - PubMed
  40. Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):218-24 - PubMed
  41. Crit Rev Oncol Hematol. 2018 Feb;122:83-91 - PubMed
  42. Acta Neurochir (Wien). 2012 Apr;154(4):569-74 - PubMed
  43. Annu Int Conf IEEE Eng Med Biol Soc. 2016 Aug;2016:4403-4406 - PubMed
  44. CNS Oncol. 2015;4(5):341-6 - PubMed
  45. Cancer. 2009 Sep 1;115(17):3969-78 - PubMed
  46. J Neurooncol. 1997 Aug;34(1):85-101 - PubMed
  47. Acta Neuropathol. 2016 Jun;131(6):803-20 - PubMed
  48. Curr Treat Options Neurol. 2014 Apr;16(4):284 - PubMed
  49. Cochrane Database Syst Rev. 2015 Jun 29;(6):CD009229 - PubMed
  50. Neuroimage. 2011 Jun 1;56(3):992-1000 - PubMed
  51. Neurology. 2018 Oct 2;91(14):657-662 - PubMed
  52. Neurooncol Pract. 2019 Mar;6(2):124-133 - PubMed

Publication Types